Bavarian, mpox vaccine
Bavarian says mpox vaccine approved by EU regulator for adolescents
LONDON (Reuters) -Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an outbreak in parts of Africa.
Gavi to obtain 500,000 mpox vaccine doses from Bavarian Nordic
Gavi (the Global Alliance for Vaccines and Immunization) has entered an advance purchase agreement with Bavarian Nordic to secure 500,000 doses of the modified vaccinia Ankara-Bavarian Nordic (MVA-BN) mpox vaccine. The vaccines, marketed under names including JYNNEOS and IMVANEX, are intended for supply in African countries.
EU Approves Use of Bavarian Nordic's Mpox Vaccine for Adolescents
Bavarian Nordic's mpox vaccine has gained approval for use in adolescents by the EU's drug regulator. This move is seen as essential for containing an outbreak in parts of Africa, with the World Health Organization declaring mpox a global public health emergency.
Bavarian Gets EU Approval for Mpox Vaccine for Adolescents
Bavarian Nordic A/S, one of the only companies with a vaccine approved for mpox, has received regulatory approval in Europe for the use of its jab for adolescents.
Gavi to secure Bavarian Nordic mpox vaccines for Africa
Denmark-based Bavarian Nordic and Gavi, the Vaccine Alliance yesterday announced an advance purchase agreement (APA) to secure 500,000 doses of the MVA-BN mpox vaccine (marketed as Jynneos or Imvanex) to be supplied to countries in Africa impacted by the mpox outbreak.
EU drugs watchdog backs Bavarian Nordic’s mpox vaccine for adolescents
The European Commission has greenlit Bavarian Nordic’s mpox and smallpox vaccine for approval for kids aged 12 to 17. The European Medicines Agency carried out an expedited and positive review of the data in this patient group, the company said, with the Commission accepting the regulator's opinion.
Bavarian Nordic Gets EMA Approval Of Mpox Vaccine For Adolescents
(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II variation for IMVANEX smallpox and mpox vaccine. This extends the current marketing authorization to include adolescents 12 to 17 years of age.
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger population COPENHAGEN,
Gavi to buy 500,000 mpox vaccine doses from Bavarian Nordic
The global vaccine group Gavi will buy 500,000 doses of Bavarian Nordic's mpox vaccine, its first purchase of the shot to help battle an outbreak in parts of Africa, the group said on Wednesday.
FiercePharma7h
Gavi, UK government tap Bavarian Nordic for 650,000 doses of mpox vaccine
Gavi, the Vaccine Alliance and the U.K. government ordered a combined 650,000 doses of Bavarian Nordic’s Jynneos mpox vaccine ...
This Day9h
Gavi Seals Deal with Bavarian Nordic to Secure 500,000 Mpox Vaccine Doses
It added: Bavarian Nordic A/S (OMX: BAVA) and Gavi, the Vaccine Alliance today announced an advance purchase agreement (APA) ...
Finanznachrichten4h
Bavarian Nordic A/S: Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents
Paul Chaplin, President & CEO of Bavarian Nordic, said: "We applaud EMA for their expedited review and decision to recommend approval of MVA-BN for adolescents. This represents an important ...
STAT6d
Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more
Anthem Blue Cross Blue Shield is taking an unusually hard line on doctors who it says improperly prescribed Ozempic.